Abraxane Approval History
FDA Approved: Yes (First approved January 7, 2005)
Brand name: Abraxane
Generic name: paclitaxel protein-bound
Dosage form: for Injectable Suspension
Company: American Pharmaceutical Partners, Inc. / American Bioscience, Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer
Abraxane (paclitaxel protein-bound) is an albumin-bound form of the antineoplastic agent paclitaxel indicated for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.
Development History and FDA Approval Process for Abraxane
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.